Amylyx Pharmaceuticals (NASDAQ:AMLX) Issues Earnings Results, Misses Expectations By $0.03 EPS

Amylyx Pharmaceuticals (NASDAQ:AMLX) announced its quarterly earnings results on Thursday. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.03), FiscalAI reports.

Here are the key takeaways from Amylyx Pharmaceuticals’ conference call:

• LUCIDITY top-line data is expected in late August or early September 2026 after the final participant completed the 16-week study period; database cleaning and locking are still underway, and management remains blinded to the results.
• Amylyx reported $250.8 million in cash and marketable securities at quarter-end and expects its cash runway to extend into 2028, covering anticipated avexitide milestones, including a potential 2027 launch.
• Commercial preparations are advancing ahead of a potential avexitide approval, including field medical deployment, key commercial hires, an HCP and patient education campaign, and plans to target treatment centers with concentrated PBH populations.
• Management estimates approximately 160,000 U.S. patients have post-bariatric hypoglycemia and cites high endocrinologist intent to treat with an approved therapy; a dedicated ICD-10 code becomes effective October 1, 2026, potentially improving recognition and tracking of the condition.
• Q2 operating expenses rose 7% year over year to $45.7 million, driven partly by higher legal costs, including a one-time charge, and increased commercial investment; avexitide’s approval, label breadth, and launch timing remain dependent on the pending phase III data and FDA review.

Amylyx Pharmaceuticals Stock Performance

Shares of AMLX traded up $2.34 during mid-day trading on Thursday, reaching $24.19. The company had a trading volume of 3,537,737 shares, compared to its average volume of 1,860,869. The company has a market capitalization of $2.69 billion, a price-to-earnings ratio of -16.13 and a beta of -0.21. The firm has a 50-day moving average price of $17.19 and a 200 day moving average price of $15.71. Amylyx Pharmaceuticals has a 52 week low of $7.48 and a 52 week high of $24.36.

Analyst Upgrades and Downgrades

AMLX has been the subject of several research analyst reports. Guggenheim raised their target price on shares of Amylyx Pharmaceuticals from $30.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, June 25th. Citigroup raised their price objective on shares of Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the stock a “buy” rating in a report on Monday. HC Wainwright reiterated a “buy” rating and set a $34.00 target price on shares of Amylyx Pharmaceuticals in a report on Monday, June 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research report on Friday, May 8th. Finally, Mizuho lifted their price target on Amylyx Pharmaceuticals from $21.00 to $24.00 and gave the company an “outperform” rating in a research report on Monday, July 20th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Amylyx Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $25.38.

Insider Transactions at Amylyx Pharmaceuticals

In other Amylyx Pharmaceuticals news, insider Gina Mazzariello sold 15,000 shares of the business’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $18.32, for a total value of $274,800.00. Following the sale, the insider directly owned 194,090 shares of the company’s stock, valued at approximately $3,555,728.80. The trade was a 7.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 10.90% of the company’s stock.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

A number of hedge funds have recently bought and sold shares of AMLX. Adage Capital Partners GP L.L.C. grew its position in Amylyx Pharmaceuticals by 54.5% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 8,800,000 shares of the company’s stock valued at $56,408,000 after purchasing an additional 3,102,395 shares during the last quarter. Perceptive Advisors LLC grew its holdings in shares of Amylyx Pharmaceuticals by 0.4% during the second quarter. Perceptive Advisors LLC now owns 7,902,365 shares of the company’s stock valued at $50,654,000 after buying an additional 28,017 shares during the last quarter. TCG Crossover Management LLC grew its holdings in shares of Amylyx Pharmaceuticals by 5.0% during the third quarter. TCG Crossover Management LLC now owns 6,243,812 shares of the company’s stock valued at $84,853,000 after buying an additional 300,000 shares during the last quarter. Janus Henderson Group PLC increased its position in shares of Amylyx Pharmaceuticals by 76.1% during the fourth quarter. Janus Henderson Group PLC now owns 4,465,872 shares of the company’s stock valued at $53,992,000 after acquiring an additional 1,929,639 shares in the last quarter. Finally, Millennium Management LLC lifted its position in Amylyx Pharmaceuticals by 418.6% in the 1st quarter. Millennium Management LLC now owns 3,081,853 shares of the company’s stock valued at $10,910,000 after acquiring an additional 2,487,617 shares in the last quarter. Institutional investors own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.